Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 clients • 7 examiners • 6 art units • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
ArentFox Schiff, LLP & Memorial Sloan-Kettering has 7 pending office actions in Biotechnology & Pharmaceuticals and 33400 career applications. The application history supplies broad context for the current matter set in this technology area.
The resolved allowance rate is 87.96%, and the average is 3.27 office actions per allowance. The record indicates that successful outcomes commonly involve multiple examination exchanges. Practitioners should align claim scope with detailed technical support and anticipate iterative prosecution.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | MIDDLETON, DANAYA L | 5d overdue |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | — |
| 18433538 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | WHEELER, THURMAN MICHAEL | — |
| 17414414 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | VU, JAKE MINH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | MIDDLETON, DANAYA L | 5d overdue |
| 17909310 | ANTI-CCR8 AGENTS | SULLIVAN, DENNIS JOHN | 14d |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | — |
| 18433538 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | WHEELER, THURMAN MICHAEL | — |
| 17961761 | NANOPARTICLE IMMUNOCONJUGATES | HUYNH, PHUONG N | — |
| 17414414 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | VU, JAKE MINH | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Cornell University | 3 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 2 |
| THE CURATORS OF THE UNIVERSITY OF MISSOURI | 1 |
| Max-planck-gesellschaft Zur Förderung der Wissenschaften E.v. | 1 |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1671 | 1 |
| 1619 | 1 |
| 1641 | 1 |
| 1642 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18911705 | NANOPARTICLE DRUG CONJUGATES | Cornell University | DICKINSON, PAUL W | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | Memorial Sloan Kettering Cancer Center | ZOU, NIANXIANG | 1671 | §103§112Other | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18433538 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | Cornell University | WHEELER, THURMAN MICHAEL | 1619 | §102§103§112 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 17961761 | NANOPARTICLE IMMUNOCONJUGATES | The Curators of the University of Missouri | HUYNH, PHUONG N | 1641 | §112DP | Final Rejection | — | Pending | Oct 07, 2022 |
| 17909310 | ANTI-CCR8 AGENTS | Memorial Sloan Kettering Cancer Center | SULLIVAN, DENNIS JOHN | 1642 | §112 | Final Rejection | 14d | Pending | Sep 02, 2022 |
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MIDDLETON, DANAYA L | 1674 | §101§112 | Non-Final OA | 5d overdue | Pending | Apr 19, 2022 |
| 17414414 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | Cornell University | VU, JAKE MINH | 1618 | §103§112Other | Non-Final OA | — | Pending | Jun 16, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial88.0% of resolved applications prosecuted by Arentfox Schiff, LLP & Memorial Sloan-Kettering were allowed, across 33,400 applications in USPTO records.
3.27 office actions per allowed application on average.
7 pending office actions as of October 2026, for 4 clients, before 7 examiners in 6 art units.
